810685-50-8

Basic information

• Product Name: 2,3-bis(4-chlorophenyl)furo[3.4-b]pyrazine-5,7-dione
• Synonyms: 2,3-bis(4-chlorophenyl)furo[3.4-b]pyrazine-5,7-dione
• CAS NO: 810685-50-8
• Molecular Weight: 371.179
• Mol File: 810685-50-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2,3-bis(4-chlorophenyl)furo[3.4-b]pyrazine-5,7-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-bis(4-chlorophenyl)furo[3.4-b]pyrazine-5,7-dione(810685-50-8)
• EPA Substance Registry System: 2,3-bis(4-chlorophenyl)furo[3.4-b]pyrazine-5,7-dione(810685-50-8)

Safety Data

• Hazardous Substances Data: 810685-50-8(Hazardous Substances Data)

Upstream product

• 3457-46-3 4,4'-dichlorobenzil 
• 4254-20-0 4,4'-dichlorobenzoin 
• 104-88-1 4-chlorobenzaldehyde 
• 810685-47-3 5,6-bis(4-chlorophenyl)-pyrazine-2,3-dicarbonitrile 
• 810685-49-5 5,6-bis(4-chlorophenyl)pyrazine-2,3-dicarboxylic acid 

Downstream Products

• 810685-52-0 5,6-bis(4-chlorophenyl)-N-piperidin-1-yl-3-(piperidin-1-ylcarbonyl)pyrazine-2-carboxamide 
• 811436-91-6 5,6-bis(4-chlorophenyl)-3-(4-methyl-4,5-dihydrooxazol-2-yl)-pyrazine-2-carboxylic acid tert-butyl ester 
• 810685-51-9 5,6-bis(4-chlorophenyl)-3-(piperidin-1-ylcarbonyl)pyrazine-2-carboxylic acid 
• 811441-51-7 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylic acid 
• 811436-88-1 5,6-bis(4-chlorophenyl)-3-(tert-butoxycarbonyl)-pyrazine-2-carboxylic acid 

Relevant articles and documents

THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I); and pharmaceutically acceptable salts thereof, in which R1 and R2 independently represent phenyl, thienyl, pyridyl, C1-10alkyl, C1-10alkoxy or C3-1

2,3-SUBSTITUTED 5,6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATORS

The present invention relates to 2,3-substituted 5,6-diaryl-pyrazine derivatives, e.g. 5,6-diaryl-3-heterocyclylpyrazine-2-ester derivatives of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them. The compounds are cannabinoid receptor 1 (CB1) modulators.